Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

XDx Launches AlloMap® Molecular Expression Testing in Germany

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Non-invasive blood test helps physicians monitor risk of acute cellular rejection in stable heart transplant recipients.

XDx, Inc. announced the launch of AlloMap® Molecular Expression Testing in Germany. AlloMap is XDx’s easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient’s risk of acute cellular rejection without requiring the use of endomyocardial biopsy. Heart transplant specialists initiated use of AlloMap in selected German hospitals in March 2012, and XDx expects to make AlloMap available to additional German, Swiss and Austrian transplant centers throughout the second quarter of this year in the first stage of a broader European launch.

In the United States, AlloMap is FDA-cleared and has been on the market since 2005. In 2010, a study called Invasive Monitoring Attenuation Through Gene Expression (IMAGE) demonstrated that AlloMap was non-inferior to biopsy with respect to clinical outcomes, including survival and absence of graft dysfunction. In addition, the study showed a reduction in the use of biopsies by 75% on average. Patients also gave a higher satisfaction rating to AlloMap than biopsy for the method used for detecting rejection. Based on these results, AlloMap testing is recommended in the practice guidelines of the International Society for Heart and Lung Transplantation (ISHLT).

In April 2011, AlloMap received a CE mark in the European Union under the In Vitro Diagnostics Directive. Findings from a European study (CARGO II) of AlloMap will be presented at the ISHLT’s 32nd Annual Meeting & Scientific Sessions being held April 18-21, 2012 in Prague, Czech Republic. CARGO II was designed to further validate results from the landmark multi-center, prospective, validation study known as the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study completed by XDx in the US.

Pierre Cassigneul, President and CEO of XDx, said, “We are excited to initiate the European AlloMap launch in Germany, which represents the largest heart transplant market in the EU, which overall is similar in size to the US market. Closely following the launch in Germany, we will soon begin making AlloMap available in Switzerland and Austria. By next year, we anticipate expanding our reach to additional large European markets.”

Jörg Stypmann, M.D., PhD, transplant cardiologist in the Department of Cardiology and Angiology of the University Hospital Münster, Germany, commented, “Heart transplant recipients must be regularly monitored for acute cellular rejection, and currently in our institution they undergo up to 15 invasive, protocol biopsy procedures in their lifetime. There is a great clinical need to determine a patient’s individual risk of rejection in order to spare them so many uncomfortable procedures, which also involve moderate risk of adverse events. We think that AlloMap, a non-invasive test with its high negative predictive value, can provide a much-needed alternative strategy to monitor effectiveness of immunosuppressive therapy during the first year after heart transplantation and in the longer term. AlloMap also can potentially reduce the number of right ventricular biopsies in stable patients.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Genetic Test Could Improve Blood Cancer Treatment
Testing for genetic risk factors could improve treatment for myeloma – a cancer of the blood and bone marrow – by helping doctors identify patients at risk of developing more aggressive disease.
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!